GE HealthCare Technologies Inc. (GEHC)

NASDAQ: GEHC · USD

$75.6

+4.47 (+6.3%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-05

Our latest published analysis: GEHC rated Hold

GE HealthCare Technologies Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$68.3 / share

Potential value

$81.1 / share

Upside to FV

+6.2%

from $75.6

Moat

7.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$29.2B
Revenue (ttm)	21.6B
Net income (ttm)	2.2B
EPS (ttm)	$4.73
Shares out	451.7M
P/E (trailing)	16.0x
P/E (forward)	12.1x
Dividend	$0.16 (0.21%)
Volume	8,089,827
Beta	0.85

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 21.6B
Net income (ttm): 2.2B
EPS (ttm): $4.73
P/E (trailing): 16.0x
P/E (forward): 12.1x
Market cap: $29.2B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$17.59B	$18.34B	$19.55B	$19.67B	$20.63B	+4.1%
Gross profit	$7.17B	$7.18B	$7.92B	$8.21B	$8.25B	+3.5%
Operating income	$2.80B	$2.52B	$2.44B	$2.63B	$2.76B	-0.3%
Net income	$2.25B	$1.92B	$1.57B	$1.99B	$2.08B	-1.9%
EPS (diluted)	$4.95	$4.22	$3.03	$4.34	$4.55	-2.1%
EBITDA	$3.54B	$3.17B	$2.44B	$3.67B	$3.79B	+1.7%
R&D	$816.0M	$1.03B	$1.21B	$1.31B	$1.26B	+11.5%
SG&A	$3.56B	$3.63B	$4.28B	$4.27B	$4.23B	+4.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base60%

Price target

$68.29

+6.2% from spot

The Base scenario projects a target of $68.29 with an assigned probability of 60.0%, representing an expected return of 6.2% relative to $64.29 (as of 2026-10-02). This path requires steady execution across core diagnostic imaging replacement cycles, durable recurring service revenues, and gradual operating margin expansion from standalone supply chain efficiencies. The scenario would be disconfirmed if hospital equipment procurement decelerates into contraction or if pricing concessions in international markets impair gross margin stability. Investors will be able to verify this trajectory through book-to-bill ratios and quarterly imaging segment growth across upcoming reporting periods.

Installed base replacement cycles sustain steady mid-single-digit organic growth across core imaging modalities
United States hospital demand remains resilient, offsetting measured procurement velocity in China
Post-separation operating margin expansion tracks gradual corporate cost optimization

Bull20%

Price target

$81.12

+26.2% from spot

The Bull scenario projects a target of $81.12 with an assigned probability of 20.0%, offering an implied return of 26.2% compared to $64.29 (as of 2026-10-02). Realizing this potential value path requires accelerated hospital fleet modernization driven by artificial intelligence integration, robust post-spin supply chain rationalization, and a sharp rebound in public healthcare procurement across emerging markets. This thesis would be falsified if customer adoption of new digital features stalls or if hospital capital budget constraints cap equipment pricing. Investors will assess progress through sequential order momentum and margin leverage across upcoming fiscal quarters.

Rapid hospital adoption of AI-enhanced imaging platforms drives accelerated hardware replacement cycles
Standalone operational leverage and procurement efficiencies lift operating margins toward peer medtech levels
Stabilization and policy recovery in China tender activity restores emerging market revenue growth

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($68.29). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
7.9%	$73.9	$75.8	$77.8	$80.1	$82.6
8.4%	$69.4	$71.0	$72.7	$74.5	$76.5
8.9%	$65.6	$66.9	$68.3	$69.8	$71.4
9.4%	$62.3	$63.4	$64.6	$65.8	$67.2
9.9%	$59.4	$60.3	$61.3	$62.4	$63.5

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E12.1

P25 n/aP50 n/aP75 n/a

Trailing P/E14.8

P25 n/aP50 n/aP75 n/a

ROE20

P25 n/aP50 n/aP75 n/a

ROIC13.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GEHC indicators

Market & fundamental data

Available fields

268

Groups with data

Currency

USD

Showing 268 of 268 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001932393
Company name	GE HealthCare Technologies Inc.
Country	United States
Country code	US
CUSIP number	36266G107
Earnings date	2026-10-28
Earnings time	bmo
Employees	54,000
Employees change	1,000
Employees growth	1.89%
Enterprise value	$41.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1892
In index	SP500, NASDAQ100
Industry	Medical Devices
Is primary listing	Yes
Is SPAC	No
ISIN number	US36266G1076
Last 10-K release date	2026-02-04
Last earnings date	2026-10-28
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$34.1B
Market cap category	Large-Cap
Next earnings date	2027-02-03
Options	Yes
Price	$75.59
Price currency	USD
Sector	Healthcare
SIC code	3844
Stock price date	2026-10-28
Symbol	GEHC
U.S. state	Illinois
Website	https://www.gehealthcare.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	15.43x
Average P/E ratio (3Y)	19.05x
Average P/E ratio (5Y)	19.17x
Earnings yield	6.26%
EV/Earnings	19.34x
EV/EBIT	13.06x
EV/EBITDA	10.93x
EV/FCF	22.04x
EV/Sales	1.92x
FCF / EV yield	4.54%
FCF yield	5.47%
Forward EV/Sales	1.86x
Forward P/E	14.23x
Forward P/S	1.54x
Graham number	52.2891
Graham upside	-31.56%
Industry forward P/E	19.74x
Industry P/E	39.16x
Lynch fair value	$23.65
Lynch upside	-69.04%
P/(FCF - SBC) ratio	19.87x
P/(OCF - SBC) ratio	15.25x
P/B ratio	2.77x
P/E ratio	15.98x
P/FCF ratio	18.27x
P/OCF ratio	14.29x
P/S ratio	1.6x
PEG ratio	1.54x
Price/EBITDA ratio	9.06x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	14.73%
EBITDA margin	17.61%
Effective tax rate	20.25%
FCF margin	8.73%
Gross margin	39.94%
Operating margin	14.73%
Pretax margin	12.81%
Profit margin	9.95%
Profit per employee	$39,870
Profitable quarters	20
Profitable years	7
Revenue per employee	$400,685
ROA	5.35%
ROA (5Y)	5.96%
ROCE	10.79%
ROE	20.01%
ROE (5Y)	19.24%
ROIC	13.15%
ROIC (5Y)	13.87%
SBC / revenue	0.7%
Tax / revenue	2.59%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-2.07%
EPS growth (Q)	39.05%
EPS growth (QoQ)	9.82%
EPS growth 3Y	11.96%
EPS growth quarters	1
EPS growth years	2
FCF growth	34.93%
FCF growth (Q)	64.18%
FCF growth (QoQ)	1,066.18%
FCF growth 3Y	3.11%
FCF growth 5Y	5.43%
Gross profit growth	4.61%
Gross profit growth (Q)	11.81%
Gross profit growth 3Y	3.93%
Gross profit growth 5Y	5.01%
Net income growth	-2.84%
Net income growth (Q)	37.89%
Net income growth (QoQ)	9.63%
Net income growth 3Y	11.91%
Net income growth 5Y	-31.08%
Net income growth quarters	1
Net income growth years	2
OCF growth	30.54%
OCF growth (Q)	52.95%
OCF growth (QoQ)	439.88%
OCF growth 3Y	4.89%
OCF growth 5Y	7.44%
Operating income growth	12.25%
Operating income growth (Q)	9.99%
Operating income growth 3Y	4.19%
Operating income growth 5Y	3.26%
Revenue growth	6.87%
Revenue growth (Q)	7.19%
Revenue growth (QoQ)	4.12%
Revenue growth 3Y	3.91%
Revenue growth 5Y	4.74%
Revenue growth quarters	9
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-526M
Depreciation and amortization	$622M
EBIT	$3.2B
EBITDA	$3.8B
EPS	$4.73
FCF per share	$4.18
Financing cash flow	$-547M
Free cash flow	$1.9B
Free cash flow minus SBC	$1.7B
Gross profit	$8.6B
Income taxes	$561M
Investing cash flow	$-3B
Net borrowing	$-124M
Net cash flow	$-1.2B
Net income	$2.2B
Operating cash flow minus SBC	$2.3B
Operating income	$3.2B
Revenue	$21.6B
Stock-based compensation	$152M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$25.69
Debt / EBITDA	2.57
Debt / equity	0.84
Debt / FCF	5.28
Goodwill	$15.1B
Interest coverage	8.37
Long-term assets	$26.9B
Long-term liabilities	$17.7B
Net cash (debt)	$-7.1B
Net cash / market cap	-20.63%
Net debt / EBITDA	1.87
Net debt / equity	0.6
Net debt / FCF	3.77
Piotroski F-Score	6
Property, plant and equipment	$3.2B
Shareholders' equity	$11.9B
Tangible book value	$-5.3B
Tangible book value per share	$-11.81
Total assets	$38.4B
Total cash	$2.9B
Total debt	$10B
Total liabilities	$26.5B
WACC	7.6%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.58
Current assets	$11.5B
Current liabilities	$8.8B
Current ratio	1.3
Inventory turnover	5.27
Net working capital	$-171M
Quick ratio	0.77
Working capital	$2.7B
Working capital turnover	9.62

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.55%
Dividend growth	3.57%
Dividend growth years	2
Dividend payment date	2026-11-13
Dividend payment years	4
Dividend payout frequency	Quarterly
Dividend per share	$0.16
Dividend yield	0.21%
Ex-dividend date	2026-10-23
FCF payout ratio	4.58%
Last dividend	$0.04
Payout ratio	3.69%
Shareholder yield	0.76%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$67.03
1D price change	6.29%
1M price change	13.37%
1M total return	13.44%
1W price change	7.56%
1W total return	7.62%
1Y price change	-3.59%
1Y return CAGR	-3.39%
1Y total return	-3.39%
20-day SMA	$68.44
200-day SMA	$69.90
3M price change	23.59%
3M total return	23.66%
3Y price change	19.72%
3Y return CAGR	6.37%
3Y total return	20.35%
50-day SMA	$68.36
50-day SMA vs 200-day SMA	50under200
52-week high	$89.77
52-week high date	2026-01-08
52-week low	$58.75
52-week low date	2026-04-29
6M price change	7.18%
6M total return	7.3%
All-time high	$94.80
All-time high date	2025-02-13
All-time low	$53.00
All-time low date	2022-12-19
Average true range (ATR)	$2.07
Average volume	3.6M
Beta (1Y)	0.78
Beta (2Y)	1.32
Beta (5Y)	0.85
Change from 52-week high	-15.8%
Change from 52-week low	28.66%
Change from all-time high	-20.32%
Change from all-time low	42.53%
Change from open	-0.55%
Day's gap	6.88%
Dollar volume	$611.5M
High price	$77.88
Low price	$74.64
Monthly RSI	53.39
Open price	$76.00
Position in 52-week range	29.17%
Premarket change	8.52%
Premarket close	$71.11
Premarket price	$77.17
Premarket volume	297.8K
Previous close	$71.11
Price vs 150-day SMA	12.7%
Price vs 20-day SMA	10.37%
Price vs 200-day SMA	8.06%
Price vs 50-day SMA	10.5%
Relative volume	2.22
RSI	72.28
Sharpe ratio	-0.04
Sharpe ratio (3Y)	0.22
Sortino ratio	0.11
Sortino ratio (3Y)	0.48
Volume	8.1M
Weekly RSI	58.96
YTD price change	-7.9%
YTD total return	-7.72%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	450.2M
Float percentage	99.67%
Shares change (QoQ)	-0.22%
Shares change (YoY)	-0.55%
Shares held by insiders	0.22%
Shares held by institutions	93.83%
Shares outstanding	451.7M
Short % of float	4.3%
Short % of shares	4.29%
Short ratio	5.2 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	356

Deeper analysis on GEHC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this GEHC report

What is the latest published GEHC stock rating?

GE HealthCare Technologies Inc. is shown with Hold in the latest published report, analyzed 2026-10-05. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GEHC analysis?

The full latest published report, analyzed 2026-10-05, lives at /stocks/GEHC/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for GEHC?

The latest published report analyzed 2026-10-05 gives GEHC a fair value of USD 68 and a potential value of USD 81. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the GEHC page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-05). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldGEHC · Fair value $68.3+6.2%

Read full analysis →

GE HealthCare Technologies Inc. (GEHC)

Our latest published analysis: GEHC rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · GEHC

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All GEHC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on GEHC

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	6.0
Management	6.5
Balance Sheet	5.0
Profitability	6.0
Revenue Growth	6.0
Risk Assessment	6.5
Competitive Moat	7.5
Earnings Quality	6.5
Capital Efficiency	5.5